Quince Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Update
Rhea-AI Summary
Quince Therapeutics (Nasdaq: QNCX) reported second quarter 2026 results highlighting the completed stock‑for‑stock acquisition of Orphai Therapeutics, adding lead asset LAM‑001, an inhaled rapamycin for multiple serious pulmonary diseases. Concurrently, the company closed a private placement with $115 million in gross upfront proceeds and potential for up to an additional $83 million upon warrant exercise.
Cash and cash equivalents were $116 million as of June 30, 2026, which Quince expects will fund operations through year‑end 2028. R&D expense was $5.5 million versus $6.6 million a year earlier, while G&A rose to $16.6 million, driven by non‑cash stock‑based compensation and higher professional fees. Net loss was $75.5 million, or $12.31 per share, compared with a $16.0 million loss in the prior‑year quarter. Quince advanced LAM‑001 into Phase 2b PH‑ILD and continued a Phase 2 BOS trial, supported by Phase 2a data showing clinically meaningful improvements in six‑minute walk distance and pulmonary vascular resistance.
Positive
- $115 million gross upfront from private placement, plus up to $83 million in warrants
- Quarter‑end cash and equivalents of $116 million, expected to fund operations through 2028
- Completed Orphai acquisition, adding late‑stage pulmonary candidate LAM‑001 to the pipeline
- Phase 2a LAM‑001 data showed mean 6MWD gain of 67.4–81.3 meters
- R&D expense declined to $5.5 million from $6.6 million year over year
Negative
- Quarterly net loss increased to $75.5 million from $16.0 million year over year
- Recorded $59.0 million acquired in‑process R&D expense related to Orphai
- Booked an intangible asset impairment charge of $67.8 million in the first half of 2026
- G&A expense rose to $16.6 million from $3.3 million, driven by stock‑based compensation and fees
- Total stockholders’ equity remained negative at $(35.3) million as of June 30, 2026
- Two reverse stock splits (1‑for‑10 and 1‑for‑20) effected in April and June 2026
News Explained
The closed financing adds $103.6 million net cash while leaving future ownership impact dependent on undisclosed conversion and warrant terms.
The Orphai acquisition is complete and the concurrent private placement is closed: Quince received
The release reports
Quince also completed a 1-for-10 reverse split on
Using first-quarter operating cash use as the comparison basis, the
Sources and calculations
- Quince Therapeutics second-quarter 2026 results and corporate update (2026-08-14)
- Dilution definition (2026-07-17)
- Reverse stock split definition (2026-07-17)
- Quince Therapeutics first-quarter 2026 fundamentals (2026Q1)
- Offering gross vs quarterly operating cash outflow, in days of cash use $115,000,000 / ($7,627,000 / 90) = [object Object]
Key Figures
Previous Earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Nov 12 | Third quarter earnings | Positive | -1.8% | Completed Phase 3 enrollment and reported cash runway into Q2 2026 |
| Aug 11 | Second quarter earnings | Positive | +14.4% | Completed enrollment, secured financing, and reported strategic partnership |
| May 13 | First quarter earnings | Negative | -7.8% | Considered early enrollment conclusion because of cash runway and slower enrollment |
| Mar 24 | Fiscal year earnings | Positive | -2.1% | Reported clinical progress, regulatory designations, and $40.8 million cash |
| Nov 13 | Third quarter earnings | Positive | +19.5% | Reported trial enrollment, $47.8 million cash, and development plans |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Tag-specific earnings reactions were mixed, with positive announcements sometimes aligning with gains and sometimes diverging into declines.
Key Terms
mTOR inhibitor medical
private placement financing financial
pulmonary vascular resistance medical
6MWD medical
convertible preferred stock financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
Completed acquisition of Orphai Therapeutics, adding LAM-001, an inhaled formulation of rapamycin for the treatment of multiple serious, underserved pulmonary diseases, to pipeline
LAM-001 Phase 2b data in PH-ILD anticipated in the first quarter of 2028; Phase 2 data in BOS anticipated in the first quarter of 2027
Closed private placement financing, receiving
Cash and cash equivalents of
SOUTH SAN FRANCISCO, Calif., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Quince Therapeutics, Inc. (Nasdaq: QNCX), a clinical stage biopharmaceutical company focused on the development of novel, disease modifying therapies for serious underserved diseases, today provided a business update and reported financial results for the second quarter ended June 30, 2026.
“This was a transformational quarter for the company with a renewed focus on a differentiated, late-stage pulmonary pipeline anchored by LAM-001 as well as a strengthened balance sheet to support our development plans,” said Dr. Brigette Roberts, former CEO of Orphai Therapeutics and Chief Corporate Affairs Officer of Quince Therapeutics. “We are pleased to have initiated the Phase 2b trial of LAM-001 for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD) and look forward to releasing top line bronchiolitis obliterans syndrome post lung transplant (BOS) data in the first quarter of next year. Inhibition of the mTOR pathway via LAM-001 has the potential to offer PH-ILD and BOS patients a new treatment option that is designed to target and potentially reverse key elements of the underlying pathophysiology of these devastating diseases.”
Second Quarter and Recent Business Highlights
- Completed Orphai acquisition and closed a concurrent
$1 15 million private placement financing. On May 18, 2026, Quince completed a stock-for-stock merger to acquire Orphai, a clinical-stage biotechnology company, bringing Orphai’s lead program, LAM-001, an inhaled formulation of rapamycin (an mTOR inhibitor), into the pipeline. LAM-001 is being developed for the treatment of serious, underserved pulmonary diseases, including PH-ILD, BOS, and sarcoidosis-associated pulmonary hypertension (SAPH).
Concurrent with the acquisition, Quince entered into a definitive agreement for a private placement financing with gross upfront proceeds of$115 million , yielding net proceeds of$103.6 million after deducting placement agent and other offering expenses of$11.4 million , for the purchase of shares of Series C non-voting convertible preferred stock and up to an additional$83 million upon the exercise of warrants (including warrants issued to former Orphai stockholders).
- Advancing the LAM-001 clinical program. Clinical sites have been activated, and the company is actively screening subjects for its Phase 2b trial of LAM-001 in PH-ILD. Topline data is anticipated in the first quarter of 2028. The company also continues to expect data from the Phase 2 trial of LAM-001 in BOS in the first quarter of 2027. The Phase 2 trial of LAM-001 in SAPH is anticipated to begin in late 2026, with data expected in the fourth quarter of 2028.
- Presented new LAM-001 Phase 2a data at the American Thoracic Society (ATS) Conference. Data from the Phase 2a trial of LAM-001 in 10 adult patients with PAH and PH-ILD demonstrated clinically meaningful improvement across functional, hemodynamic, and biomarker measures of disease. A mean improvement in six-minute walk distance (6MWD) of 67.4 meters and a mean reduction in pulmonary vascular resistance (PVR) (supine) of
33.9% at 24 weeks were seen in PH-ILD patients. A mean 6MWD improvement of 81.3 meters and a mean reduction in PVR (supine) of28.1% were seen in the combined evaluable population of PAH and PH-ILD patients. The drug was generally well tolerated in both populations. - Formed Scientific Advisory Board (SAB). Appointed five internationally recognized experts in pulmonary medicine to an SAB – Dr. Paul Yu, Dr. Aaron Waxman, Dr. Steven Nathan, Dr. Steve Hays, and Dr. Robert Baughman – who Quince believes will be instrumental in helping to progress the development of LAM-001 across multiple pulmonary indications.
Second Quarter 2026 Financial Results
Cash position: Cash and cash equivalents were
Research and development (R&D) expense: R&D expense for the three months ended June 30, 2026 was
General and administrative (G&A) expense: G&A expense for the three months ended June 30, 2026 was
Net loss: Quince reported a net loss of
Shares outstanding: 978,022 shares of common stock were outstanding as of June 30, 2026.
On April 10, 2026, Quince effected a reverse stock split of all shares of its issued and outstanding common stock at a ratio of 1-for-10. On June 29, 2026, Quince effected a reverse stock split of all shares of its issued and outstanding common stock at a ratio of 1-for-20. All issued and outstanding shares of common stock and share-based awards’ exercise prices and per share data herein have been adjusted, on a retrospective basis, to reflect the reverse stock splits. The number of authorized shares and par value of the common stock were not adjusted because of the reverse stock splits.
About LAM-001
LAM-001 is a proprietary, investigational, once-daily inhaled formulation of rapamycin, also known as sirolimus. LAM-001’s potential as a disease-modifying agent in PH stems from its ability to inhibit mTOR-mediated pulmonary arterial smooth muscle cell proliferation, to limit endothelial cell dysfunction, and to suppress inflammatory signaling, leading to improvement in pulmonary vascular remodeling. The mTOR pathway has been shown to be activated in pulmonary arteries of patients with PH, and mTOR inhibition with rapamycin has been shown to reverse smooth muscle cell hyperproliferation and to attenuate pulmonary vascular remodeling and cardiopulmonary dysfunction in multiple published nonclinical models. Additionally, in published non-clinical studies, hyperactive mTOR signaling has been shown to promote fibroblast activation, myofibroblast differentiation, and extracellular matrix deposition in injured or inflamed lung tissue, and mTOR inhibition has been shown to exert direct antifibrotic activity, suppressing profibrotic cytokine signaling, reducing collagen accumulation, and attenuating parenchymal fibrosis. These effects are particularly relevant in PH-ILD, where vascular remodeling and progressive fibrosis evolve in parallel and amplify pulmonary vascular load. LAM-001 is designed to enhance pulmonary delivery and to reduce systemic exposure of rapamycin, offering a promising, potentially disease-modifying, therapy for multiple pulmonary diseases.
LAM-001 is currently being studied in multiple indications including PH-ILD, a serious and progressive condition affecting an estimated 200,000 patients between the U.S. and Europe. Based on compelling Phase 2a data presented at the American Thoracic Society (ATS) in May 2026, the company has advanced LAM-001 into a Phase 2b PH-ILD trial and data is anticipated in the first quarter of 2028. LAM-001 is also being evaluated in a Phase 2 study in bronchiolitis obliterans syndrome post lung transplant (BOS), a serious complication with an estimated prevalence of ~30K patients between the U.S. and Europe by 2032. The trial is fully enrolled, and data is anticipated in the first quarter of 2027. In late 2026, the company also plans to initiate a Phase 2 study of LAM-001 in sarcoidosis-associated pulmonary hypertension (SAPH), a severe complication of pulmonary sarcoidosis with no approved therapy, that affects an estimated ~60K patients in the U.S. and Europe.
About Quince Therapeutics, Inc.
Quince Therapeutics, Inc. is committed to transforming the lives of patients facing serious, underserved diseases by developing disease-modifying therapies to treat their conditions. The company is currently developing LAM-001 for the treatment of PH-ILD, BOS, and SAPH. A Phase 2a study in PH patients has been completed, a Phase 2 clinical study in BOS patients is ongoing, a Phase 2b study in PH-ILD is ongoing, and a Phase 2 study in SAPH is anticipated to begin in late 2026. By pioneering innovative approaches, the company aims to offer new hope and improved quality of life to patients worldwide.
Forward-Looking Statements
Statements in this news release contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. All statements, other than statements of historical facts, may be forward-looking statements. Forward-looking statements contained in this news release may be identified by the use of words such as “believe,” “may,” “should,” “expect,” “anticipate,” “plan,” “believe,” “estimated,” “potential,” “intend,” “will,” “can,” “seek,” or other similar words. Examples of forward-looking statements include, among others, statements relating to the design and potential benefits of LAM-001, including as a disease-modifying therapy for pulmonary disease; anticipated regulatory and development processes and timelines, including the expected timing to initiate the planned Phase 2 trial of LAM-001 in SAPH, the expected timing for data readouts from the ongoing Phase 2 trial of LAM-001 in BOS and the ongoing Phase 2b trial of LAM-001 in PH-ILD; the Phase 2a data of LAM-001 in PAH and PH-ILD supporting continued development of LAM-001 in PH-ILD and the potential benefit across exercise capacity, pulmonary hemodynamics, cardiac stress and lung function; observed improvements in 6MWD and PVR in the Phase 2a trial potentially suggesting broader effects on cardiopulmonary physiology; the estimated patient populations in the U.S. and Europe for PH-ILD, BOS and SAPH; the potential advantages of mTOR inhibitors in PH-ILD, BOS and SAPH; and the company’s anticipated cash runway. Forward-looking statements are based on Quince’s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict and could cause actual results to differ materially from what the company expects. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, but are not limited to: clinical results may not be indicative of results that may be observed in the future, including in larger populations; potential safety and other complications related to LAM-001; the ability to obtain and maintain regulatory approval; competition in the company’s industry; the scope, progress and expansion of developing LAM-001; the size and growth of the market(s) therefor and the rate and degree of market acceptance thereof vis-à-vis alternative therapies; the company’s ability to attract or retain key management, members of the board of directors and other personnel; the company’s ability to fund its operations and clinical development plans, including its anticipated cash runway; the impacts of general macroeconomic and geopolitical conditions on the company’s business and financial position; and other risks and uncertainties described in the section titled “Risk Factors” in the company’s Amendment No. 2 to its Current Report on Form 8-K filed with the Securities and Exchange Commission (SEC) on July 30, 2026 and other reports as filed with the SEC. Forward-looking statements contained in this news release are made as of this date, and Quince undertakes no duty to update such information except as required under applicable law.
| Three Months Ended March 31, | Six Months Ended June 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | 5,461 | 6,553 | 12,306 | 14,698 | ||||||||||||
| Acquired in-process research and development | 59,000 | — | 59,000 | — | ||||||||||||
| General and administrative | 16,626 | 3,342 | 20,893 | 8,131 | ||||||||||||
| Gain on Orphai Acquisition | (1,305 | ) | — | (1,305 | ) | — | ||||||||||
| Intangible asset impairment charge | — | — | 67,808 | — | ||||||||||||
| Fair value adjustment for contingent consideration | — | 532 | (64,330 | ) | 2,456 | |||||||||||
| Total operating expenses | 79,782 | 10,427 | 94,372 | 25,285 | ||||||||||||
| Loss from operations | (79,782 | ) | (10,427 | ) | (94,372 | ) | (25,285 | ) | ||||||||
| Fair value adjustment for debt | — | (501 | ) | 12,168 | (945 | ) | ||||||||||
| Fair value adjustment for warrants | 4,507 | (4,464 | ) | 35,623 | (4,464 | ) | ||||||||||
| Warrant issuance costs | (874 | ) | (872 | ) | (874 | ) | (872 | ) | ||||||||
| Interest income | 584 | 311 | 744 | 717 | ||||||||||||
| Other income (expense), net | 152 | (29 | ) | 1,871 | (116 | ) | ||||||||||
| Net income (loss) before income tax expense | (75,413 | ) | (15,982 | ) | (44,840 | ) | (30,965 | ) | ||||||||
| Income tax benefit (expense) | (75 | ) | (67 | ) | 5,264 | (114 | ) | |||||||||
| Net loss | $ | (75,488 | ) | $ | (16,049 | ) | $ | (39,576 | ) | $ | (31,079 | ) | ||||
| Net loss per share - basic and diluted (1) | $ | (12.31 | ) | $ | (68.75 | ) | $ | (12.01 | ) | $ | (137.17 | ) | ||||
| Weighted-average common shares outstanding - basic and diluted (1) | 6,132,845 | 233,431 | 3,295,727 | 226,571 | ||||||||||||
| June 30, 2026 | December 31, 2025 | |||||||||||||||
| Cash, cash equivalents, and investments | $ | 115,981 | $ | 17,752 | ||||||||||||
| Total assets | 123,995 | 93,523 | ||||||||||||||
| Total liabilities | 15,508 | 129,237 | ||||||||||||||
| Series C Redeemable Convertible Preferred Stock | 143,811 | — | ||||||||||||||
| Total stockholders' equity (deficit) | (35,324 | ) | (35,714 | ) | ||||||||||||
| (1) Adjusted prior period net loss per share and weighted average of common shares outstanding to reflect the 1-for-10 reverse stock split effected on April 10, 2026 and the 1-for-20 reverse stock split effected on June 29, 2026 | ||||||||||||||||
Contacts
Corey Davis, Ph.D.
LifeSci Advisors, LLC
cdavis@lifesciadvisors.com
212-915-2577
